Levi Garraway, Roche CMO
Roche’s PD-L1 player Tecentriq fails PhIII for ovarian cancer
Roche’s hit-and-miss record on Tecentriq has posted another miss.
The pharma giant reported this morning that the PD-L1 checkpoint failed a Phase III trial for …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
